Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.

@article{OMalley2009TopoisomeraseIA,
  title={Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.},
  author={Frances P. O'Malley and StephenK. Chia and Dongsheng Tu and Lois E. Shepherd and Mark Norman Levine and Vivien H. C. Bramwell and Irene L Andrulis and Katherine I. Pritchard},
  journal={Journal of the National Cancer Institute},
  year={2009},
  volume={101 24},
  pages={1735-6; author reply 1736-7}
}
BACKGROUND Amplification or deletion of the topoisomerase II alpha (TOP2A) gene in breast cancers has been postulated to be more closely associated with responsiveness to anthracycline-containing chemotherapy than amplification of the human epidermal growth factor receptor type 2 (HER2) gene. METHODS We studied 438 tumors from 710 premenopausal women with node-positive breast cancer who received cyclophosphamide, epirubicin, and 5-fluorouracil (CEF) or cyclophosphamide, methotrexate, and 5… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS